Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873944 | 1.00 | RAB9A (0.34) | RAB9AALDH1A1NPC1KDM1ASMN1; SMN2 | |
| SCHEMBL1053120 | 1.00 | RAB9A (0.34) | RAB9AALDH1A1NPC1KDM1ASMN1; SMN2 | |
| SCHEMBL6161857 | 1.00 | RAB9A (0.34) | RAB9AALDH1A1NPC1KDM1ASMN1; SMN2 | |
| SCHEMBL1053121 | 1.00 | RAB9A (0.34) | RAB9AALDH1A1NPC1KDM1ASMN1; SMN2 | |
| SCHEMBL1051198 | 1.00 | — | — | |
| SCHEMBL873943 | 1.00 | RAB9A (0.34) | RAB9AALDH1A1NPC1KDM1ASMN1; SMN2 | |
| SCHEMBL6161860 | 1.00 | RAB9A (0.34) | RAB9AALDH1A1NPC1KDM1ASMN1; SMN2 | |
| SCHEMBL46404 | 0.97 | — | — | |
| SCHEMBL8967946 | 0.93 | RAB9A (0.32) | RAB9AALDH1A1NPC1HDAC4HDAC2 | |
| SCHEMBL8967953 | 0.93 | RAB9A (0.32) | RAB9AALDH1A1NPC1HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113614057-B | Process for producing alpha-allylated cycloalkanone | 花王株式会社 | 2024-09-27 | — | — | CN | disclosed |
| CN-113614058-B | Process for producing alpha-allylated cycloalkanone | 花王株式会社 | 2024-09-27 | — | — | CN | disclosed |
| EP-3943477-B1 | METHOD FOR PRODUCING ALPHA-ALLYLATION CYCLOALKANONE | KAO CORP (JP) | 2024-08-07 | — | — | EP | disclosed |
| US-11685705-B2 | Method for producing α-allylated cycloalkanone | KAO CORPORATION (JP) | 2023-06-27 | — | — | US | disclosed |
| US-11524929-B2 | Method for producing alpha-allylated cycloalkanone | KAO CORPORATION (JP) | 2022-12-13 | — | — | US | disclosed |
| US-20220153671-A1 | METHOD FOR PRODUCING ALPHA-ALLYLATED CYCLOALKANONE | KAO CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
| US-20220153672-A1 | METHOD FOR PRODUCING ALPHA-ALLYLATED CYCLOALKANONE | KAO CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
| EP-3943477-A1 | METHOD FOR PRODUCING ALPHA-ALLYLATION CYCLOALKANONE | Kao Corporation (JP) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943476-A1 | METHOD FOR PRODUCING alpha- ALLYLATED CYCLOALKANONE | Kao Corporation (JP) | 2022-01-26 | — | — | EP | disclosed |
| CN-113614057-A | Process for preparing alpha-allylated cycloalkanones | 花王株式会社 | 2021-11-05 | — | — | CN | disclosed |
| CN-113614058-A | Process for preparing alpha-allylated cycloalkanones | 花王株式会社 | 2021-11-05 | — | — | CN | disclosed |
| WO-2020189670-A1 | METHOD FOR PRODUCING α – ALLYLATED CYCLOALKANONE | 花王株式会社 | 2020-09-24 | — | — | WO | disclosed |
| EP-0893442-B1 | LYMPH-ABSORBABLE IMIDAZOLE DERIVATIVES | SHIONOGI & CO (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-6054591-A | LYMPHOTROPIC ANTI-AIDS AGENT | SHIONOGI & CO., LTD. (JP) | 2000-04-25 | — | — | US | disclosed |
| EP-0893442-A1 | LYMPH-ABSORBABLE IMIDAZOLE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1999-01-27 | — | — | EP | disclosed |
| US-4206112-A | α-Nitrosoketal dimers and production of α-oximinoketals therefrom | ALLIED CHEMICAL CORPORATION (US) | 1980-06-03 | — | — | US | disclosed |
| US-4045422-A | NITROSATING AN ALKOXYALKENE | ALLIED CHEMICAL CORPORATION (US) | 1977-08-30 | — | — | US | disclosed |
| US-4013709-A | REACTION OF ENOL ETHER WITH HYDROGEN PEROXIDE, BORON CATALYST | BAYER AKTIENGESELLSCHAFT (DT) | 1977-03-22 | — | — | US | disclosed |
| US-4001303-A | BORON COMPOUND; COMPOUNDS, 5; COMPOUNDS, 6; CATALYSTS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524929-B2 | Method for producing alpha-allylated cycloalkanone | ADH1A, ADH1C, ADH5 | RAB9A 3379/4885ALDH1A1 32/4885NPC1 2662/4885 |
| US-20220153671-A1 | METHOD FOR PRODUCING ALPHA-ALLYLATED CYCLOALKANONE | ADH1A, ADH1C, ADH5 | RAB9A 3379/4885ALDH1A1 32/4885NPC1 2662/4885 |
| US-20220153672-A1 | METHOD FOR PRODUCING ALPHA-ALLYLATED CYCLOALKANONE | AKR1C3, PYM1, AKR1A1 | RAB9A 3808/4885ALDH1A1 165/4885NPC1 1216/4885 |
| US-11685705-B2 | Method for producing α-allylated cycloalkanone | AKR1C3, GALK1, PYM1 | RAB9A 3794/4885ALDH1A1 169/4885NPC1 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.